BriaCell Therapeutics Corp.
BCTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001610820
No open-market purchases or sales by BriaCell Therapeutics Corp. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $1.58M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in BriaCell Therapeutics Corp. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −6 vs. Q4 2023
- Shares held
- 2.19M
- −299.5K (−12.0%) vs. Q4 2023
- Total value
- $6.38M
- −$8.22M (−56.3%) vs. Q4 2023
- New holders
- 1
- 8 more added
- Sold out
- 7
- 6 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BCTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $1.58M |
| Q1 2026 | 16 | $1.62M |
| Q4 2025 | 13 | $69.2K |
| Q3 2025 | 13 | $136.5K |
| Q2 2025 | 16 | $181.1K |
| Q1 2025 | 14 | $94.1K |
| Q4 2024 | 26 | $379.1K |
| Q3 2024 | 22 | $538.1K |
| Q2 2024 | 20 | $452.0K |
| Q1 2024 | 20 | $6.38M |
| Q4 2023 | 26 | $14.6M |
| Q3 2023 | 21 | $17.0M |
| Q2 2023 | 21 | $17.9M |
| Q1 2023 | 21 | $19.4M |
| Q4 2022 | 21 | $12.3M |
| Q3 2022 | 22 | $14.3M |
| Q2 2022 | 22 | $17.0M |
| Q1 2022 | 18 | $33.5M |
| Q4 2021 | 20 | $10.9M |
| Q3 2021 | 21 | $4.77M |
| Q2 2021 | 24 | $20.3M |
| Q1 2021 | 10 | $1.45M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding BriaCell Therapeutics Corp.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Lynwood Capital Management Inc. | 1,597,750 | $4.57M | 27.08% | +17,105+1.1% | Added |
| Bank of Montreal | 134,241 | $520.5K | 0.00% | +80,125+148.1% | Added |
| Redmond Asset Management, LLC | 133,069 | $380.6K | 0.12% | −500−0.4% | Reduced |
| K.J. Harrison & Partners Inc | 87,044 | $249.2K | 0.04% | +6,329+7.8% | Added |
| Onyx Bridge Wealth Group LLC | 50,000 | $108.5K | 0.02% | +20,000+66.7% | Added |
| Summit Trail Advisors, LLC | 35,000 | $100.1K | 0.00% | 00.0% | Unchanged |
| Sabby Management, LLC | 34,222 | $97.9K | 0.64% | +34,222 | New |
| Morgan Stanley | 23,664 | $67.7K | 0.00% | −41,137−63.5% | Reduced |
| Bank of America Corp | 17,999 | $51.5K | 0.00% | +200+1.1% | Added |
| TD Waterhouse Canada Inc. | 12,050 | $41.4K | 0.00% | 00.0% | Unchanged |
| HighTower Advisors, LLC | 14,450 | $41.0K | 0.00% | −1,437−9.0% | Reduced |
| Susquehanna International Group, LLP | 12,357 | $35.3K | 0.00% | −49,965−80.2% | Reduced |
| Renaissance Technologies LLC | 12,200 | $35.0K | 0.00% | +1,300+11.9% | Added |
| Concord Wealth Partners | 10,775 | $30.8K | 0.01% | 00.0% | Unchanged |
| Citadel Advisors LLC | 6,427 | $18.4K | 0.00% | −8,526−57.0% | Reduced |
| National Bank of Canada | 7,500 | $16.7K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 3,600 | $10.0K | 0.00% | −15,000−80.6% | Reduced |
| Advisor Group Holdings, Inc. | 1,032 | $2.95K | 0.00% | +1,020+8,500.0% | Added |
| Tower Research Capital LLC (TRC) | 787 | $2.25K | 0.00% | +259+49.1% | Added |
| Rosenberg Matthew Hamilton | 12 | $34 | 0.00% | 00.0% | Unchanged |
| Wasatch Advisors Inc | 0 | $0 | 0.00% | −267,410−100.0% | Sold out |
| Marex Group plc | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| Natixis | 0 | $0 | 0.00% | −22,281−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −12,500−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −10,972−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −15−100.0% | Sold out |